Advertisement Protect sells pain drugs patent portfolio to Grunenthal - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Protect sells pain drugs patent portfolio to Grunenthal

Protect Pharmaceutical, a New Jersey-based drug delivery and new product development company, has completed the sale of two patents and patents-applications related to pain drugs to German specialty pharmaceutical company Grunenthal.

Protect still retains the patents related to abuse deterrent and once daily gastro-retentive drug delivery platforms and the corresponding three other ongoing projects.

In the near term, Protect intends to proceed with a comprehensive program to develop and commercialize once-daily drugs for diabetic neuropathic pain, fibromyalgia, postherpetic neuralgia and epilepsy.

Protect also plans to develop and commercialize once-daily opioid combinations as well as abuse-deterrent opioid combinations for moderate to severe pain.